Amalgamated Bank’s aTyr Pharma ATYR Stock Holding History

Amalgamated Bank’s Portfolio ATYR Stock Details ATYR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-3,014	Closed	-$2K	–	2865
2025 Q4	$2K	Buy	3,014 +43	+1%	+$35	﹤0.01%	2927
2025 Q3	$2K	Hold	2,971	–	–	﹤0.01%	2958
2025 Q2	$15K	Buy	+2,971	New	+$11.7K	﹤0.01%	2252

Other funds holding ATYR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Amalgamated Bank's ATYR Position: Q1 2026 in Review

Amalgamated Bank sold out of aTyr Pharma (ATYR) in Q1 2026, closing a stake of 3,014 shares — an estimated $2K sold.

Amalgamated Bank first reported a position in ATYR in Q2 2025 and held it in 3 quarters. The position peaked at $15K in Q2 2025. 111 funds tracked by Wall St. Rank hold ATYR as of Q1 2026.

Amalgamated Bank reported no remaining aTyr Pharma position as of Q1 2026 after selling out during the quarter.
Amalgamated Bank sold 3,014 aTyr Pharma shares in Q1 2026, an estimated $2K.
Amalgamated Bank first reported a position in aTyr Pharma in Q2 2025 and held it in 3 quarters.
Amalgamated Bank's aTyr Pharma position peaked at $15K in Q2 2025.
111 funds tracked by Wall St. Rank held aTyr Pharma as of Q1 2026.

Based on Amalgamated Bank's 13F filing for Q1 2026, filed 8 May 2026.